Microplasmin - Diabetic Retinopathy: Phase II trial to evaluate microplasmin for the treatment of Diabetic Macular Edema (DME).
- First unmasked data due to be presented at ASRS Conference in New York, 4 October, 2009
ThromboGenics is currently investigating microplasmin in the treatment of diabetic retinopathy, as it seeks to extend the range of indications for which the product could be potentially used. ThromboGenics completed the enrolment of a Phase II trial of microplasmin intravitreal injection for treatment of DME (MIVI II DME) in March 2009. The first unmasked data from this trial will be presented at the ASRS (American Society of Retina Specialists) Conference in New York on 4 October, 2009 by Professor Stalmans, KULeuven. This trial is designed as the initial step in evaluating the utility of microplasmin in patients with diabetes, a group which is more prone to eye disease such as diabetic retinopathy, due to their underlying medical condition.
Diabetic retinopathy is a major cause of visual loss and the leading cause of blindness in patients aged 20-60. Studies in this patient population have shown that there is a great variability in the type and level of adhesion seen between the vitreous and the retina.
TB-402 - Phase II trial assessing its long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery.
- Phase II trial proceeding well and ahead of schedule
TB-402 is a novel long acting anticoagulant that is being developed for
the prevention of deep vein thrombosis (DVT) following orthopedic surgery.
The Phase II trial is proceeding well, with the first two cohorts (100
patients per cohort) of the study enrolled in just six months. We expect the
third and final patient cohort to start recruiting shortly, after review
|SOURCE ThromboGenics NV|
Copyright©2009 PR Newswire.
All rights reserved